Compare CarMax, Inc (KMX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Zimmer Biomet Holdings Inc — how do they compare? CarMax, Inc trades at $52.61 (market cap $7.64B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.2× CarMax, Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| KMX | ZBH | |
|---|---|---|
Market Cap | $7.64B | $16.95B |
Volume | 3,610,116 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $103.98 |
52-Week Low | $30.88 | $79.58 |
Typical Hold Time | 49 Days | 89 Days |
Enterprise Value | $25.34B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $53.79, up 0.96% with a bearish technical outlook despite recent earnings beats. The company reported strong Q2 2027 results with EPS of $1.16 beating expectations by 58%, driven by 19.5% revenue growth to $7.9 billion. Valuation metrics show a P/E of 25.37 and P/S of 0.28, while profitability remains challenged with a 1.06% net margin. The stock faces resistance near $54-55 with support at $52-53 levels.
KMX shows early turnaround progress with improved sales volume and earnings, but faces margin pressure and high debt levels. The consensus price target of $58.89 suggests 9.5% upside potential, though analyst sentiment is cautious with 62% hold ratings. Key risks include competitive pricing pressure and macroeconomic sensitivity to used car demand.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
